Everolimus for Advanced Pancreatic Neuroendocrine Tumors

By J. Stockman. 2012

1,571 citations recorded by the source corpus.

Subfields: Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/dec2f2d3c873467c332348a962730aa623168f0a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. C. Porta
2. A. Mosca
3. C. Paglino

In Oncology

1. A. Klein
2. C. Porta
3. A. Mosca
4. C. Paglino

Citations in the corpus

• Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease (2023, background): “Everolimus has reported promising anticancer efficacy in patients with pancreatic neuroendocrine tumors during clinical trials (RADIANT-3, NCT00510068) and received FDA approval.(269) Everolimus was given approval by the FDA in the year 2016 for clinical use in patients with neuroendocrine tumors of”
• The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours (2013, background): “Everolimus has been studied in more than 1,000 patients with NET and has been included in several clinical trials (RADIANT-1, RADIANT-2, RADIANT-3 trials, RAMSETE trial).”
• Targeting PI3K/Akt/mTOR Signaling in Cancer (2014, background): “, RECORD1 in RCC, RADIANT-3 in pNET, and BOLERO-2 in hormone receptor-positive, HER2-negative, advanced breast cancer) were comparable (30, 44, 48), as summarized in Table 1.”
• Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). (2012, background): “The success of such an approach is well illustrated by the results of clinical trials investigating the use of TRK inhibitors for MTC (103) and pancreatic NET, and mTOR inhibitors for pancreatic NET (59, 60).”
• Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas (2017, background): “6 months in the placebo arm, a highly statistically significant difference that led to its approval in pNET.(132,133) In the phase III trial called RADIANT-4, which randomized 302 patients with advanced, progressive nonfunctional NETs of the lungs and GI tract 2:1 to either 10mg everolimus daily or ”
• Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. (2015, background): “1 month increase in median progression-free survival [166].”
• Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study (2015, result): “Taken together with results from the previous RADIANT-3 study in pancreatic neuroendocrine tumours (Yao et al, 2011), the findings from RADIANT-4 study provide robust, practice-changing evidence to support the antitumour efficacy of everolimus across a broad range of neuroendocrine tumours,…”